Daniel S. Grosu, MD, MBA

Dr. Grosu is the Founder and Managing Partner of GENOPRAXIS. He most recently served as Chief Medical Officer at Sequenom, Inc. until its acquisition by LabCorp, Inc. Previously, Dr. Grosu was at Illumina, Inc., where he served as the Company’s first Chief Medical Officer. He established the Medical Affairs and Clinical Development functions at Illumina, and led the team that performed the clinical studies for the first FDA 510(k) cleared and CE marked next-generation sequencing (NGS) IVD platform and IVD assay. He also played a key role in setting up Illumina’s clinical development strategy and operations to support companion diagnostic co-development with Amgen; the Extended RAS Panel, approved by the FDA in 2017, was the world’s first NGS-based PMA IVD. 

Earlier in his career, Dr. Grosu held positions of increasing responsibility at Siemens Medical Solutions, Bayer HealthCare Pharmaceuticals, and Johnson & Johnson. He holds an MD (with Distinction in Research) from Saint Louis University School of Medicine (Missouri, USA) and an MBA from the University of Oxford (United Kingdom). 

Dr. Grosu is a sought-after speaker and adviser on Genomic Medicine topics, including non-invasive prenatal screening (NIPS), liquid biopsy, and inherited disorders.